Charles Mather Net Worth

The estimated Net Worth of Charles E Iv Mather is at least $44.2 Thousand dollars as of 26 May 2023. Mr. Mather owns over 3,000 units of Eyenovia Inc stock worth over $44,200 and over the last 12 years he sold EYEN stock worth over $0. In addition, he makes $0 as Independent Director at Eyenovia Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Mather EYEN stock SEC Form 4 insiders trading

Charles has made over 13 trades of the Eyenovia Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of EYEN stock worth $7,470 on 26 May 2023.

The largest trade he's ever made was buying 7,000 units of Eyenovia Inc stock on 18 May 2022 worth over $14,210. On average, Charles trades about 1,163 units every 118 days since 2013. As of 26 May 2023 he still owns at least 77,544 units of Eyenovia Inc stock.

You can see the complete history of Mr. Mather stock trades at the bottom of the page.

Charles Mather biography

Charles E. Mather IV serves as Independent Director of the Company. Since October 2019, Mr. Mather has been Managing Director, Equity Capital Markets at Suntrust Robinson Humphrey, Inc. Prior to that, since March 2015, Mr. Mather has been Managing Director, Co-Head of Equity Capital Markets at BTIG, LLC. From December 2009 to February 2015, he was the Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott, LLC. Between May 2007 and September 2008, Mr. Mather was the head of the Structured Equity Group at Jefferies Group Inc. Prior to that, Mr. Mather held various senior investment banking positions at Cowen and Company, including as Co-Head of the Private Equity Group. Mr. Mather serves on the board Wentz LLC. Mr. Mather also served on the board of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) until February 2019 and The Finance Company of Pennsylvania until August 2017. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.

How old is Charles Mather?

Charles Mather is 60, he's been the Independent Director of Eyenovia Inc since 2018. There are 4 older and 7 younger executives at Eyenovia Inc. The oldest executive at Eyenovia Inc is Ernest Mario, 81, who is the Independent Director.

What's Charles Mather's mailing address?

Charles's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.

Insiders trading at Eyenovia Inc

Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant, and Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.

What does Eyenovia Inc do?

eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.

Complete history of Mr. Mather stock trades at Tonix Pharmaceuticals Corp and Eyenovia Inc

Eyenovia Inc executives and stock owners

Eyenovia Inc executives and other stock owners filed with the SEC include:

• Tsontcho Ianchulev,
  Chief Executive Officer, Director, Chief Medical Officer
• Dr. Tsontcho Ianchulev M.P.H., M.D., MPH,
  CEO, Pres, Chief Medical Officer & Director
• John Gandolfo,
  Chief Financial Officer, Secretary
• John P. Gandolfo CPA,
  CFO & Sec.
• Michael Rowe,
  Vice President - Commercial
• Jennifer Clasby,
  Vice President - Clinical Operations
• Michael M. Rowe,
  Chief Operating Officer
• Fredric Eshelman,
  Independent Chairman of the Board
• Tram Bui,
  IR Contact Officer
• Anthony Sun,
  Independent Director
• Charles Mather,
  Independent Director
• Ernest Mario,
  Independent Director
• Kenneth Lee,
  Independent Director
• Curt Labelle,
  Director
• Luke Clauson,
  Vice President - Research &Development and Manufacturing
• Norbert Lowe,
  VP of Sales & Marketing
• Alexander Lobo,
  Investor Contact
• Andrew D. Jones,
  Chief Financial Officer
• Julia A Haller,
  
• Bren Kern,
  Chief Operating Officer
• Pharmaceutical Co., Ltd. Senju,
  10% owner
• Shuhei Yoshida,
  Director
• Stuart M. Grant,
  
• Stephen Keith Benjamin,
  
• Rachel Jacobson,
  Director
• Ellen R Strahlman,
  Director
• Michael S Geltzeiler,
  Director
• Ram Palanki,
  Director